Register Login
Register to leave comments
  • News bot Aug. 18, 2026, 11:02 a.m.

    📋 GENPREX, INC. (GNPX) - Clinical Trial Update

    Filing Date: 2026-08-18

    Accepted: 2026-08-18 07:01:23

    Event Type: Clinical Trial Update

    Event Details:

    GENPREX, INC. (GNPX) Announces Clinical Trial Update GENPREX, INC. (GNPX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: Common Stock

    🔬 Clinical Development Pipeline (GENPREX, INC.):

    Product Type Development Stage Therapeutic Area Source
    Investigator's Treatment of Choice Drug Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    Platinum-Based Chemotherapy Drug Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov
    ramucirumab Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    docetaxel Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    pembrolizumab Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    quaratusugene ozeplasmid Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    atezolizumab Other Phase PHASE1 Small Cell Lung Cancer Extensive Stage ClinicalTrials.gov
    Diphenhydramine Other Phase PHASE1 Lung Cancer ClinicalTrials.gov
    Dexamethasone Other Phase PHASE1 Lung Cancer ClinicalTrials.gov
    Erlotinib Other Phase PHASE1 Lung Cancer ClinicalTrials.gov
    DOTAP:Chol-TUSC2 Other Phase PHASE1 Lung Cancer ClinicalTrials.gov
    osimertinib Other Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: GENPREX, INC.
    • Ticker Symbol: GNPX

Search

News categories